[ CAS No. 1205037-95-1 ] {[proInfo.proName]}

Name: 1205037-95-1|trans-3-Aminocyclobutanol hydrochloride|95%
Brand: Ambeed
SKU: A234293
Price: 9.0 USD
Availability: InStock
Rating: 95 (40 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 1205037-95-1 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 1205037-95-1 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 1205037-95-1 ]

SDS Specification

Alternatived Products of [ 1205037-95-1 ]

Product Details of [ 1205037-95-1 ]

CAS No. :	1205037-95-1	MDL No. :	MFCD17214232
Formula :	C₄H₁₀ClNO	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	XUMSHCRPQCZRGX-UHFFFAOYSA-N
M.W :	123.58	Pubchem ID :	53308466
Synonyms :

Calculated chemistry of [ 1205037-95-1 ]

Physicochemical Properties

Num. heavy atoms :	7
Num. arom. heavy atoms :	0
Fraction Csp3 :	1.0
Num. rotatable bonds :	0
Num. H-bond acceptors :	2.0
Num. H-bond donors :	2.0
Molar Refractivity :	30.06
TPSA :	46.25 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	No
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-7.04 cm/s

Lipophilicity

Log Po/w (iLOGP) :	0.0
Log Po/w (XLOGP3) :	0.02
Log Po/w (WLOGP) :	0.27
Log Po/w (MLOGP) :	-0.16
Log Po/w (SILICOS-IT) :	-0.12
Consensus Log Po/w :	0.0

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	2.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-0.62
Solubility :	29.7 mg/ml ; 0.241 mol/l
Class :	Very soluble
Log S (Ali) :	-0.54
Solubility :	35.4 mg/ml ; 0.286 mol/l
Class :	Very soluble
Log S (SILICOS-IT) :	0.51
Solubility :	400.0 mg/ml ; 3.24 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.79

Safety of [ 1205037-95-1 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P280-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302-H315-H319-H332-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 1205037-95-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 1205037-95-1 ]

[ 1205037-95-1 ] Synthesis Path-Downstream 1~17

1
2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-methyl-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [ No CAS ]
[ 1205037-95-1 ]
[ 1422772-61-9 ]
[ 1422772-60-8 ]

Reference： [1]Journal of Medicinal Chemistry,2013,vol. 56,p. 1677 - 1692

2
[ 1414772-65-8 ]
[ 1205037-95-1 ]
[ 1426928-48-4 ]

Yield	Reaction Conditions	Operation in experiment
54 mg		In an ice bath, 25.4 mg (0.635 mmol) sodium hydride (60% dispersion in mineral oil) were dispensed in 2 mL of anhydrous THF. 52.9 mg (0.43 mmol) trans-3- aminocyclobutanol hydrochloride in 2 mL of a 1 : 1 mixture of anhydrous DMF and anhydrous THF were slowly added. After complete addition, stirring at 0C was continued for 15 min. 100 mg (0.287 mmol) of 6-chloro-3-(5-methoxy-1 -benzofuran- 2-yl)imidazo[1 ,2-b]pyridazine were added, the ice bath was removed and the resulting mixture was stirred for 72 h at 40 C. The reaction mixture was cooled to rt and a freshly prepared mixture of 9 mg (0.225 mmol) sodium hydride (60% dispersion in mineral oil) and 18 mg (0.146 mmol) <strong>[1205037-95-1]trans-<strong>[1205037-95-1]3-aminocyclobutanol hydrochloride</strong></strong> in 1 mL of a 1 : 1 mixture of anhydrous DMF and anhydrous THF were added to the reaction mixture. Stirring at 40 C was continued for 18 h. The reaction mixture was carefully poured into water. The aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over magnesium sulfate, and concentrated. The crude product was purified by HPLC to give 54 mg of the title compound as a solid material. 1H-NMR (300 MHz, DMSO-d6), delta [ppm] = 2.53 (4H), 3.68-3.77 (1 H), 3.79 (3H), 5.47- 5.58 (1 H), 6.90 (1 H), 7.00 (1 H), 7.26 (1 H), 7.48-7.57 (2H), 8.09-8.17 (2H). LC-MS (Method 3): Rt = 0.76 min; MS (ESIpos) m/z = 351 [M+H]+.

Reference： [1]Patent: WO2013/34570,2013,A1 .Location in patent: Page/Page column 115

3
[ 1205037-95-1 ]
[ 1426928-75-7 ]
[ 1426928-47-3 ]

Yield	Reaction Conditions	Operation in experiment
44 mg		In an ice bath, 33.5 mg (0.838 mmol) sodium hydride (60% dispersion in mineral oil) were dispensed in 2 mL of anhydrous THF. 69.1 mg (0.559 mmol) trans-3- aminocyclobutanol hydrochloride in 2 mL of a 1 : 1 mixture of anhydrous DMF and anhydrous THF were slowly added. After complete addition, stirring at 0C was continued for 15 min. 100mg (0.279 mmol) of 6-chloro-3-(5-chloro-1 -benzofuran-2- yl)imidazo[1 ,2-b]pyridazine were added, the ice bath was removed and the resulting mixture was stirred for 72 h at 40 C. The reaction mixture was carefully poured into water. The aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over magnesium sulfate, and concentrated. The crude product was purified by HPLC to give 44 mg of the title compound as a solid material. 1H-NMR (300 MHz, DMSO-d6), delta [ppm] = 3.65-3.80 (1 H), 5.46-5.58 (1 H), 7.03 (1 H), 7.30-7.38 (1 H), 7.60 (1 H), 7.63-7.70 (1 H), 7.81 (1 H), 8.12-8.20 (1 H) (methylene groups on cyclobutyl moiety not visible, likely hidden under DMSO-peak). LC-MS (Method 3): Rt = 0.83 min; MS (ESIpos) m/z = 355 [M+H]

Reference： [1]Patent: WO2013/34570,2013,A1 .Location in patent: Page/Page column 114

4
[ 1414772-61-4 ]
[ 1205037-95-1 ]
[ 1426928-09-7 ]

Yield	Reaction Conditions	Operation in experiment
32 mg		In an ice bath, 44.5 mg (1 .12 mmol) sodium hydride (60% dispersion in mineral oil) were dispensed in 5 mL of anhydrous THF. 91 .6 mg (0.742 mmol) trans-3- aminocyclobutan-1 -ol (hydrochloride salt) were slowly added. Stirring at 0 C was continued for 15 min. 100 mg (0.371 mmol) of intermediate 2 were added, the ice bath was removed and the resulting mixture was stirred for 5 days at 40 C. The reaction mixture was carefully poured into water. The aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over magnesium sulfate, and concentrated. The crude product was purified by HPLC to give 32 mg of the title compound as a solid material. 1H-NMR (300 MHz ,DMSO-d6), delta [ppm]= 2.49-2.57 (2H), 3.72 (2H), 5.53 (1 H), 7.01 (1 H), 7.31 (2H), 7.58-7.67 (2H), 7.71 -7.77 (1 H), 8.1 1 -8.19 (2H). LC-MS (Method 3): Rt = 0.73 min; MS (ESIpos) m/z = 321 [M+H]+.

Reference： [1]Patent: WO2013/34570,2013,A1 .Location in patent: Page/Page column 83

5
[ 1414772-77-2 ]
[ 1205037-95-1 ]
[ 1443499-80-6 ]

Yield	Reaction Conditions	Operation in experiment
22 mg		At 0C 84 mg (0.68 mmol) trans-3-aminocylcobutanol hydrochloride in 2 mL of a 1 :1 mixture of anhydrous THF and anhydrous DMF were added to 41 mg (1 mmol) sodium hydride (60% in mineral oil) in 2 mL anhydrous THF. After 15 min of stirring on the ice bath, 100 mg (0.34 mmol) of 6-chloro-3-(furo[3,2-c]pyridin-2- yl)imidazo[1 ,2-£>]pyridazine were added. The ice bath was removed and the mixture was stirred for 72 h at 40 C. The reaction mixture was poured into water and extracted with ethyl acetate. The combined organic phases and the aqueous phases were concentrated separately and then they were combined to purify the residue by HPLC. to give 22 mg of the title compound as solid material. 1H-NMR (300 MHz, DMSO-ds), delta [ppm]= 2.46 (4H), 3.55-3.72 (1 H), 5.33-5.55 (1 H), 6.95-7.11 (1 H), 7.57-7.80 (2H), 8.10-8.26 (2H), 8.41 -8.58 (1 H), 8.95-9.11 (1 H). LC-MS (Method 3): Rt = 0.48 min; MS (ESIpos) m/z = 322 [M+H]

Reference： [1]Patent: WO2013/87581,2013,A1 .Location in patent: Page/Page column 96

6
[ 64-18-6 ]
[ 1414772-77-2 ]
[ 1205037-95-1 ]
trans-3-[3-(furo[3,2-c]pyridin-2-yl)imidazo[1,2-b]pyridazin-6-yl]oxy}cyclo-butanamine formic acid salt [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
40 mg		To a stirred suspension of <strong>[1205037-95-1]trans-<strong>[1205037-95-1]3-aminocyclobutanol hydrochloride</strong></strong> (110 mg) in anhydrous THF (6 mL) and anhydrous DMF (3 mL) was added sodium hydride (60%w/w in oil; 52 mg) at 0 C and the mixture was stirred at 0 C for 30 minutes. 6-Chloro-3-(furo[3,2-c]pyridin-2-yl)imidazo[1 ,2-b]pyridazine (80 mg) and potassium carbonate (204 mg) was added and the mixture was stirred at room temperature for 72 h. A half-saturated solution of sodium chloride was added and the mixture was extracted with ethyl acetate. Aminophase-silica-gel chromatography followed by preparative reverse phase HPLC gave a solid that was triturated with dichloromethane to give 40 mg of the title compound. 1H-NMR (300 MHz, DMSO-d6, detected signals of the formic acid salt), delta [ppm] = 2.50-2.64 (4H), 3.76 (1 H), 5.59 (1 H), 7.04 (1 H), 7.66-7.74 (2H), 8.13-8.21 (2H), 8.39 (1 H), 8.46 (1 H), 9.03 (1H). LC-MS (Method 2): Rt = 0.47 min; MS (ESIpos) m/z = 322 [M+H]

Reference： [1]Patent: WO2013/87581,2013,A1 .Location in patent: Page/Page column 82

7
[ 1414773-00-4 ]
[ 1205037-95-1 ]
[ 1443499-62-4 ]

Yield	Reaction Conditions	Operation in experiment
61 mg		At 0C 91 mg (0.74 mmol) trans-3-aminocylcobutanol hydrochloride were added to 44 mg (1.11 mmol) sodium hydride (60% in mineral oil) in 4 mL anhydrous THF. After 15 min of stirring on the ice bath, 150 mg (0.37 mmol) of 6-chloro-3-(4- methoxyfuro[3,2-c]pyridin-2-yl)imidazo[1 ,2-b]pyridazine were added. The ice bath was removed and the mixture was stirred for 72 h at 40" C. The mixture was again cooled to 0-5 C additional amounts of 68 mg (0.56 mmol) trans-3- aminocylcobutanol hydrochloride and 29 mg (0.74 mmol) sodium hydride (60% in mineral oil) werde added. Stirring at 40 "C was continued for 18 h. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, and concentrated. The residue was purified by HPLC to give 61 mg of the title compound as solid material. 1H-NMR (300 MHz, DMSO-d6), delta [ppm]= 2.51 -2.58 (4H), 3.39-3.48 (2H), 3.79-3.85 (1 H), 4.06 (3H), 5.39-5.49 (1 H), 7.05 (1 H), 7.35-7.42 (1 H), 7.48 (1 H), 8.07 (1 H), 8.13-8.22 (2H). LC-MS (Method 3): Rt - 0.69 min; MS (ESIpos) m/z = 352 [M+H]

Reference： [1]Patent: WO2013/87581,2013,A1 .Location in patent: Page/Page column 72

8
[ 64-18-6 ]
[ 1415504-33-4 ]
[ 1205037-95-1 ]
trans-3-[3-(furo[2,3-c]pyridin-2-yl)imidazo[1,2-b]pyridazin-6-yl]oxy}-cyclobutanamine formic acid salt [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
21 mg		To a stirred suspension of <strong>[1205037-95-1]trans-<strong>[1205037-95-1]3-aminocyclobutanol hydrochloride</strong></strong> (57.5 mg, 465 pmol) in anhydrous THF (3.0 mL) and anhydrous DMF (1.5 mL) was added sodium hydride (60%w/w in oil; 27 mg) at 0 C and the mixture was stirred at 0 C for 30 minutes. 6-Chloro-3-(furo[2,3-c]pyridin-2-yl)imidazo[1 ,2-i)]pyridazine (70 mg, 155 pmol) was added and the mixture was stirred at room temperature for 16 h. A half-saturated solution of sodium chloride was added and the mixture was extracted with ethyl acetate. The solvent was removed in vacuum. Aminophase- silica-gel chromatography gave a solid that was triturated with dichloromethane. Preparative reverse phase HPLC gave 21 mg of the title compound. 1H-NMR (400MHz, DMSO-de, detected signals of the formic acid salt): delta [ppm]= 2.52 - 2.69 (m, 4H), 3.79 (br. s., 1H), 5.49 - 5.67 (m, 1H), 7.09 (d, 1H), 7.67 (s, 1 H), 7.79 (d, 1H), 8.22 (d, 1H), 8.27 (s, 1 H), 8.37 (br. s., 1H), 8.44 (d, 1H), 8.98 (s, 1 H). LCMS (Method 3): Rt = 0.47 min; MS (ESIpos) m/z = 322 [M+H]+.

Reference： [1]Patent: WO2013/87581,2013,A1 .Location in patent: Page/Page column 81-82

9
[ 1205037-95-1 ]
[ 1609105-98-7 ]
(2S,3Z)-5-[(2R,3R,5S,6S)-6-{(2E,4E)-5-[(3R,4R,5R,7S)-4-hydroxy-7-{2-[(cis-3-hydroxycyclobutyl)amino]-2-oxoethyl}-1,6-dioxaspiro[2.5]oct-5-yl]-3-methylpenta-2,4-dien-1-yl}-2,5-dimethyltetrahydro-2H-pyran-3-yl]amino}-5-oxopent-3-en-2-yl acetate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
61%	With N-ethyl-N,N-diisopropylamine; In tetrahydrofuran; N,N-dimethyl-formamide; at 20℃; for 2.5h;	Example A47 Preparation of (2S,3Z)-5-[(2R,3R,5S,6S)-6-{(2E,4E)-5-[(3R,4R,5R,7S)-4-hydroxy-7-{2-[(trans-4- hydroxycyclohexyl)amino]-2-oxoethyl}-l,6-dioxaspiro[2.5]oct-5-yl]-3-methylpenta-2,4-dien-l-yl}- 2,5-dimethyltetrahydro-2H-pyran-3-yl]amino}-5-oxopent-3-en-2-yl acetate (B141). and (2S,3Z)- 5-[(2R,3R,5S,6S)-6-{(2E,4E)-5-[(3R,4R,5R,7S)-4-hydroxy-7-{2-[(cis-3- hydroxycyclobutyl)amino]-2-oxoethyl}-l,6-dioxaspiro[2.5]oct-5-yl]-3-methylpenta-2,4-dien-l-yl}- 2,5-dimethyltetrahydro-2H-pyran-3-yl]amino}-5-oxopent-3-en-2-yl acetate (B142). and (2S,3Z)- 5-({(2R,3R,5S,6S)-6-[(2E,4E)-5-{(3R,4R,5R,7S)-4-hydroxy-7-[2-(2-methylhydrazinyl)-2- oxoethyl]-l,6-dioxaspiro[2.5]oct-5-yl}-3-methylpenta-2,4-dien-l-yl]-2,5-dimethyltetrahydro-2H- pyran-3-yl}amino)-5-oxopent-3-en-2-yl acetate (B143). and (2S,3Z)-5-({(2R,3R,5S,6S)-6- [(2E,4E)-5-{(3R,4R,5R,7S)-4-hydroxy-7-[2-(l-methylhydrazinyl)-2-oxoethyl]-l,6- dioxaspiro[2.5]oct-5-yl}-3-methylpenta-2,4-dien-l-yl]-2,5-dimethyltetrahydro-2H-pyran-3- yl}amino)-5-oxopent-3-en-2-yl acetate (B144). and (2S,3Z)-5-({(2R,3R,5S,6S)-6-[(2E,4E)-5- {(3R,4R,5R,7S)-7-[2-(l,2-dimethylhydrazinyl)-2-oxoethyl]-4-hydroxy-l,6-dioxaspiro[2.5]oct-5- yl}-3-methylpenta-2,4-dien-l-yl]-2,5-dimethyltetrahydro-2H-pyran-3-yl}amino)-5-oxopent-3-en- 2-yl acetate (B145). Step 7ii. Synthesis of (2S,3Z)-5-[(2R,3R,5S,6S)-6- {(2E,4E)-5-[(3R,4R,5R,7S)-4-hydroxy-7- {2-[(trans-4-hydroxycyclohexyl)amino]-2-oxoethyl}-l,6-dioxaspiro[2.5]oct-5-yl]-3-methylpenta-2,4- dien-l-yl}-2,5-dimethyltetrahydro-2H-pyran-3-yl]amino}-5-oxopent-3-en-2-yl acetate (B141).:To a solution of B1 (19.7 mg, 0.031 mmol, 1 eq.) dissolved in tetrahydrofuran (0.5 mL) was added trans-4- aminocyclohexanol (5.7 mg, 0.049 mmol, 1.6 eq.) After stirring for 1.5 hour, the reaction was diluted with water, extracted with dichloromethane, and the combined organics were dried over sodium sulfate and filtered. The solvents were removed in vacuo. The crude desired material was purified by reverse phase chromatography (Method A) to give B141 as a white solid. Yield: 11.8 mg, 0.019 mmol, 60%. HPLC (Protocol AA) retention time = 7.408 minutes (purity 94%). LCMS (Protocol D): m/z 633.3 [M+H]+, retention time = 0.73 minutes. lU NMR (400 MHz, DMSO-d6) delta 7.79 (d, J= 8.2 Hz, 1 H), 7.68 (d, J= 7.8 Hz, 1 H), 6.42-6.32 (m, 1 H), 6.28 (d, J= 16.0 Hz, 1 H), 6.11 (d, J= 11.5 Hz, 1 H), 5.87 (dd, J= 11.5 and 7.4 Hz, 1 H), 5.59 (dd, J= 16.0 and 5.5 Hz, 1 H), 5.54-5.45 (m, 1 H), 5.00 (d, J = 5.1 Hz, 1 H), 4.49 (d, J= 4.3 Hz, 1 H), 4.30-4.15 (m, 2 H), 3.70-3.60 (m, 2 H), 3.54-3.39 (m, 2 H), 3.26-3.20 (m, 1 H), 2.74 (d, J= 5.1 Hz, 1 H), 2.58 (d, J= 5.1 Hz, 1 H), 2.37-2.10 (m, 3 H), 1.98 (s, 3 H), 1.89-1.59 (m, 10 H), 1.51-1.41 (m, 1 H), 1.25 (d, J= 6.6 Hz, 3 H), 1.20-1.10 (m, 4 H), 1.07 (d, J = 6.2 Hz, 3 H), 0.95 (d, J= 7.4 Hz, 3 H). Step lb. Synthesis of (2S,3Z)-5-[(2R,3R,5S,6S)-6- {(2E,4E)-5-[(3R,4R,5R,7S)-4-hydroxy-7- {2-[(cis-3-hydroxycyclobutyl)amino]-2-oxoethyl} -l,6-dioxaspiro[2.5]oct-5-yl]-3-methylpenta-2,4- dien-l-yl}-2,5-dimethyltetrahydro-2H-pyran-3-yl]amino}-5-oxopent-3-en-2-yl acetate (B142). To a solution of B1 (16.2 mg, 0.026 mmol, 1 eq.) in tetrahydrofuran/NN-dimethylformamide (5: 1, 0.6 mL) at rt was added NN-diisopropylethylamine (13.7 muEpsilon, 0.078 mmol, 3 eq.) and trans-3- aminocyclobutanol hydrochloride (4.8 mg, 0.039 mmol, 1.5 eq.) (12:48 pm), and the reaction was stirred for 2 hours. Additional NN-dimethylformamide (100 uL), NN-diisopropylethylamine (13 uL, 0.078 mmol, 3 eq.) and <strong>[1205037-95-1]trans-<strong>[1205037-95-1]3-aminocyclobutanol hydrochloride</strong></strong> (3 mg, 0.024 mmol, 0.9 eq.) were added, and the reaction was stirred for an additional 30 min. The reaction was diluted with dimethyl sulfoxide and concentrated in vacuo to remove the tetrahydrofuran. The crude desired material was purified by reverse phase chromatography (Method A) to give B142 as a white solid. Yield: 9.5 mg, 0.016 mmol, 61%. HPLC (Protocol AA) retention time = 7.057 minutes (purity 91%). LCMS (Protocol D): m/z 627.1 [M+Na]+, retention time = 0.72 minutes. lU NMR (400 MHz, DMSO-d6) delta 8.03 (d, J = 7.8 Hz, 1 H), 7.79 (d, J= 8.2 Hz, 1 H), 6.42-6.32 (m, 1 H), 6.28 (d, J= 16.0 Hz, 1 H), 6.11 (d, J= 11.7 Hz, 1 H), 5.87 (dd, J= 11.7 and 7.4 Hz, 1 H), 5.59 (dd, J= 16.0 and 5.5 Hz, 1 H), 5.55-5.48 (m, 1 H), 5.07-4.97 (m, 2 H), 4.30-4.17 (m, 2 H), 3.81-3.71 (m, 1 H), 3.70-3.59 (m, 3 H), 3.54-3.46 (m, 1 H), 3.27-3.20 (m, 1 H), 2.75 (d, J= 4.9 Hz, 1 H), 2.58 (d, J= 4.9 Hz, 1 H), 2.48-2.39 (m, 2 H), 2.36-2.13 (m, 3 H), 1.98 (s, 3 H), 1.89-1.61 (m, 9 H), 1.49-1.41 (m, 1 H), 1.25 (d, J= 6.6 Hz, 3 H), 1.07 (d, J = 6.2 Hz, 3 H), 0.95 (d, J= 7.4 Hz, 3 H). Step lc. Synthesis of (2S,3Z)-5-( {(2R,3R,5S,6S)-6-[(2E,4E)-5- {(3R,4R,5R,7S)-4-hydroxy-7- [2-(2-methylhydrazinyl)-2-oxoethyl]-l,6-dioxaspiro[2.5]oct-5-yl}-3-methylpenta-2,4-dien-l-yl]-2,5- dimethyltetrahydro-2H-pyran-3-yl}amino)-5-oxopent-3-en-2-yl acetate (B143) and (2S,3Z)-5- ({(2R,3R,5S,6S)-6-[(2E,4E)-5- {(3R,4R,5R,7S)-4-hydroxy-7-[2-(l-methylhydrazinyl)-2-oxoethyl]-l,6- diox...

Reference： [1]Patent: WO2014/68443,2014,A1 .Location in patent: Page/Page column 160; 161

10
[ 24424-99-5 ]
[ 1205037-95-1 ]
[ 389890-42-0 ]

Yield	Reaction Conditions	Operation in experiment
	With triethylamine; In ethanol; at 20℃;	Synthesis of intermediate 8-b: 8-a 8-b Scheme 8 To a solution of in intermediate 26-a-HCI (10.0 g, 70.6 mmol) in ethanol (35 ml) were sequentially added TEA (35.0 ml) and Boc20 (20.0 g, 31.3 mmol) and the reaction was stirred overnight at room temperature. Volatiles were removed under reduced pressure, ethyl acetate and water were added to the residue, the organic layer was separated, washed with a saturated aqueous solution of NaHC03 and brine, dried over MgS04, filtered and concentrated under reduced pressure to provide intermediate 8-b as a white solid.

Reference： [1]Patent: WO2016/187723,2016,A1 .Location in patent: Page/Page column 56

11
[ 1205037-95-1 ]
4-hydroxy-7-(4-methoxybenzyl)-5-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)thieno[2,3-b]pyridin-6(7H)-one [ No CAS ]
4-(((1r,3r)-3-hydroxycyclobutyl)amino)-5-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)thieno[2,3-b]pyridin-6(7H)-one dihydrochloride [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
18 mg		General Method C (Amine substitution) A solution of benzoimidazol-2-yl arylpyridinone bistriflate derivate (1 equiv) in MeCN, DCM, or DMF was treated with amine (1.2-3 equiv). In the case where the amine is a salt (e.g. HCl), the amine salt was dissolved in MeOH or DMF and passed through a PoraPak Rxn CX ion exchange column to yield the free base which was added to the reaction mixture. The reaction mixture was stirred at rt or up to 45 C for 1-48 h. Solvent was removed and the crude product was purified by column chromatography or prep-HPLC to give the desired product. General Method D (Global deprotection) A solution of protected benzoimidazol-2-yl arylpyridinone derivate (1 equiv) in TFA/conc. HCl (7: 1 v/v) was heated at 80-100 C for 3-24 h. Solvent was removed and the crude product was purified by column chromatography (free base) or prep-HPLC (TFA salt) to give the desired product. To generate the desired product as a HCl salt, the free base was dissolved in MeOH and 1 M HCl-Et20 (2-4 equiv) was added at rt. The solution was stirred for 5 min and azeotroped twice with MeOH.

Reference： [1]Patent: WO2016/205942,2016,A1 .Location in patent: Page/Page column 26; 30; 43

12
[ 1205037-95-1 ]
[ 1428368-75-5 ]
(1r,3r)-3-((4-(3,5-dimethylisoxazol-4-yl)-2-nitrophenyl)amino)cyclobutan-1-ol [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
98%	With triethylamine; In N,N-dimethyl-formamide; at 20 - 60℃; for 18h;	-(4-fluoro-3-nitrophenyl)-3,5-dimethylisoxazole (8.69 g, 36.8 mmol) was dissolved in dry dimethylformamide (50 mL) and TEA (20.51 mL, 147 mmol). (lr,3r)-3- aminocyclobutanol hydrochloride (5 g, 40.5 mmol) was added and the reaction warmed to 60C and left to stir at RT for 18 h. After cooling to rt the reaction mixture was poured into ice water (300 mL) The precipitate was collected to afford (lr,3r)-3-((4- (3,5-dimethylisoxazol-4-yl)-2-nitrophenyl)amino)cyclobutanol (11.16 g, 98%) as an orange solid; Rt 1.89 min (method 1); m/z 304 (M+H)+ (ES+).

Reference： [1]Patent: WO2018/73586,2018,A1 .Location in patent: Page/Page column 109

13
[ 1205037-95-1 ]
[ 66298-49-5 ]
trans-3-((6-iodo-2-methylpyrimidin-4-yl)amino)cyclobutanol [ No CAS ]

Reference： [1]Patent: WO2018/137573,2018,A1 .Location in patent: Page/Page column 90

14
[ 1205037-95-1 ]
[ 19182-81-1 ]
(trans)-3-(4-nitro-1H-imidazol-1-yl)cyclobutanol [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
84%	With N-ethyl-N,N-diisopropylamine; In methanol;	Reaction of 1,4-dinitro-lH-imidazole (726 mg, 4.59 mmol) with (tras)-<strong>[1205037-95-1]3-aminocyclobutanol hydrochloride</strong> (471a) (560 mg, 4.53 mmol; CAS 1205037-95-1) using DIEA (0.865 mL, 4.95 mmol) in MeOH (20 mL) as reported in step-2 of General scheme for preparation of 3- substituted-(4-amino-lH-imidazol-l-yl) gave after work-up and purification by flash column chromatography [silica gel 24 g, eluting with ethyl acetate/MeOH (9: 1) in hexanes from 50- 100%] (/rara)-3-(4-nitro-lH-imidazol-l-yl)cyclobutanol (471b) (696 mg, 84 % yield) as a yellow solid; MR (300 MHz, DMSO-i) delta 8.57 (d, J= 1.5 Hz, 1H), 7.99 (d, J= 1.5 Hz, 1H), 5.30 (d, J= 4.7 Hz, 1H), 4.97 (m, 1H), 4.40 (m, 1H), 2.71 - 2.57 (m, 2H), 2.45 - 2.32 (m, 2H).

Reference： [1]Patent: WO2018/232094,2018,A1 .Location in patent: Page/Page column 611

15
[ 389890-42-0 ]
[ 1205037-95-1 ]

Yield	Reaction Conditions	Operation in experiment
90.91%	With hydrogenchloride; In 1,4-dioxane; at 0 - 20℃; for 1h;	To 74 (0.50 g, 2.67 mmol, 1.0 eq) added hydrochloric acid in dioxane (5 mE) at 00 C. The reaction mixture was stirred at room temperature for 1 h. After completion of reaction, reaction mixture was concentrated under reduced pressure to obtain crude material. This was further purified by trituration with diethylether to obtain 74.1 (0.30 g, 90.91%). MS(ES): mlz 124.58 [M+H].

Reference： [1]Patent: US2019/31664,2019,A1 .Location in patent: Paragraph 1232; 1233; 1234

16
[ 1205037-95-1 ]
2-(6-((2S,5S)-2,5-dimethylpyrrolidin-1-yl)pyridin-3-yl)-1-(2-ethoxyethyl)-1H-benzo[d]imidazole-5-carboxylic acid [ No CAS ]
2-(6-((2S,5S)-2,5-dimethylpyrrolidin-1-yl)pyridin-3-yl)-1-(2-ethoxyethyl)-N-(-3-hydroxycyclobutyl)-1H-benzo[d]imidazole-5-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
20 mg		A solution of 2-(6-((2S,5S)-2,5-dimethylpyrrolidin-1 -yl)pyridin-3-yl)-1 -(2-ethoxyethyl)-1 H- benzo[d]imidazole-5-carboxylic acid (50.0 mg, 0.122 mmol), N-methylmorpholine (0.047 mL, 0.428 mmol), and HATU (55.8 mg, 0.147 mmol) in DMF (1 .5 mL) was stirred at room temperature 15 minutes. (1 r,3r)-3-aminocyclobutan-1 -ol hydrochloride (18.15 mg, 0.147 mmol) was then added, and the reaction mixture was stirred at room temperature overnight. The reaction was filtered and then purified by reverse HPLC (15 to 55% CH3CN/(water(0.1 %-formic acid)) to afford the desired product (20 mg) as a white solid. LC- MS (ES) m/z = 478 [M+H]+. 1H NMR (400 MHz, CD3CN): delta 8.56 (d, J = 2.0 Hz, 1 H), 8.15 (s, 1 H), 8.13 (s, 1 H), 7.94 (dd, J = 2.4, 9.0 Hz, 1 H), 7.79 (dd, J = 1 .0, 8.4 Hz, 1 H), 7.61 (d, J = 8.4 Hz, 1 H), 7.37 (d, J = 5.6 Hz, 1 H), 6.60 (d, J = 8.9 Hz, 1 H), 4.62 - 4.50 (m, 3H), 4.44 (t, J = 5.1 Hz, 2H), 4.29 (br. s., 2H), 3.82 (t, J = 5.3 Hz, 2H), 3.37 (q, J = 6.9 Hz, 2H), 2.45 - 2.21 (m, 6H), 1 .77 - 1 .62 (m, 2H), 1 .20 (d, J = 6.1 Hz, 6H), 1 .02 (t, J = 7.0 Hz, 3H).

Reference： [1]Patent: WO2019/49061,2019,A1 .Location in patent: Page/Page column 376

17
[ 1205037-95-1 ]
[ 1448427-98-2 ]
C₁₁H₁₃N₅O [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
41%	With acetic acid; In acetonitrile; at 90℃; for 16h;	[00506] To a solution of Example 93a (2.0 g, 16.18 mmol) in MeCN (32 mL) was added AcOH (8mL) and Example 93b (2.12 g, 8.09 mmol). The mixture was stirred at 90C for 16 h. The mixture was cooled to r., followed by addition of IN HC1 (aq., 2 mL), which was stirred for another 2 hs.The mixture was basified by 30% NaOH (aq.) to pH = 9 and concentrated. The residue was purified by column chromatography (DCM/MeOH = 78/22) to give the desired product Example 93c (1.5 g, yield41%) as light yellow oil. LCMS [M+l]+ =232.0

Reference： [1]Patent: WO2019/51265,2019,A1 .Location in patent: Paragraph 00506

Same Skeleton Products

Related Products

Historical Records

Related Functional Groups of
[ 1205037-95-1 ]

Aliphatic Cyclic Hydrocarbons

[ 4640-44-2 ]

3-Aminocyclobutanol

Similarity: 0.95

[ 1184919-69-4 ]

3-Aminocyclopentanol hydrochloride

Similarity: 0.86

[ 1259436-59-3 ]

(1S,3R)-3-Aminocyclopentanol hydrochloride

Similarity: 0.86

[ 124555-33-5 ]

trans-3-Aminocyclopentanol hydrochloride

Similarity: 0.86

[ 1279032-31-3 ]

(1R,3S)-3-Aminocyclopentanol hydrochloride

Similarity: 0.86

Alcohols

[ 4640-44-2 ]

3-Aminocyclobutanol

Similarity: 0.95

[ 1184919-69-4 ]

3-Aminocyclopentanol hydrochloride

Similarity: 0.86

[ 1259436-59-3 ]

(1S,3R)-3-Aminocyclopentanol hydrochloride

Similarity: 0.86

[ 124555-33-5 ]

trans-3-Aminocyclopentanol hydrochloride

Similarity: 0.86

[ 1279032-31-3 ]

(1R,3S)-3-Aminocyclopentanol hydrochloride

Similarity: 0.86

Amines

[ 4640-44-2 ]

3-Aminocyclobutanol

Similarity: 0.95

[ 1184919-69-4 ]

3-Aminocyclopentanol hydrochloride

Similarity: 0.86

[ 1259436-59-3 ]

(1S,3R)-3-Aminocyclopentanol hydrochloride

Similarity: 0.86

[ 124555-33-5 ]

trans-3-Aminocyclopentanol hydrochloride

Similarity: 0.86

[ 1279032-31-3 ]

(1R,3S)-3-Aminocyclopentanol hydrochloride

Similarity: 0.86

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 1205037-95-1 ] {[proInfo.proName]}

Quality Control of [ 1205037-95-1 ]

Related Doc. of [ 1205037-95-1 ]

Product Details of [ 1205037-95-1 ]

Calculated chemistry of [ 1205037-95-1 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 1205037-95-1 ]

Application In Synthesis of [ 1205037-95-1 ]

[ 1205037-95-1 ] Synthesis Path-Downstream 1~17

Related Functional Groups of [ 1205037-95-1 ]

Aliphatic Cyclic Hydrocarbons

Alcohols

Amines

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 1205037-95-1 ]